Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective This report provides you with a landscape description and analysis of prodrug antibodies and cytokines employing conventional and novel masking technology platforms from an industry perspective as of October 2021.
The prodrug concept of masking technologies is an elegant approach to address the selectivity limitations of conventional therapeutic antibodies and cytokines. The report brings you up-to-date with information about and analysis of
Stakeholders in the field: technology and major pharmaceutical companies and investors;
Masking technologies: conventional (kinetically controlled); pH dependent and protease cleavage in the tumor microenvironment
Targets of masked antibodies and type of masked cytokine selected for development of masked biologics;
Business strategy: pure play (foundational or converted) masking technology company, diversified technology company, exit options, preferred antibody modality or type of cytokine, investment case;
Financing situation of technology companies and key investors in the field;
Partnering deals with financial terms;
Major pharmaceutical companies: preferences for masking technologies, collaboration and licensing agreements.
Background Therapeutic antibodies have become a clinically and commercially successful treatment modality with more than 100 antibodies approved for therapy and commercial sales of more than US$ 184 bln in the year 2020.However, systemic administration of monoclonal antibodies or cytokines may induce severe adverse events with mechanism-of-action effects, meaning off-tumor on-target toxicity in healthy tissue.
In order to increase the selectivity of antibodies and cytokines at the disease site, antibodies should ignore the target antigen and cytokines the receptor in normal healthy tissue and be preferentially active in the disease region. The use of antibody prodrugs is one new strategy for more specific tumor targeting of biological therapies. Conventional prodrugs are pharmacologically inactive compounds that are converted into active forms in the body after administration. They can be designed to be activated at the intended site of action, thereby lowering exposure of normal tissues to active drug and minimizing toxicity. The most common novel approach to creating antibody prodrugs are protease-activated antibodies that use antigen binding site ‘masks’. The mask is typically a recombinant protein extension of the light and/or heavy chain of the antibody that has been designed to block access to the antigen binding site and physically prevent binding of the antibody to the cognate antigen.A protease substrate sequence is also inserted between the mask and the antibody.
When the prodrug antibody enters the tumor microenvironment, upregulated proteases that are common in cancer tissues cleave the substrate sequence, the mask separates from the antibody, and the antibody becomes competent to bind to its target in the tumor.This doesn’t happen efficiently in normal tissues because there is insufficient extracellular protease activity to remove the mask.
The same principle does apply to prodrug cytokines.
Methodology This report evaluates the industry landscape of masked antibodies and cytokines in research and development. The report is based on the identification and description of 40 stakeholder, 24 of which are companies with masking technologies and 16 are pharma/biotech companies partnered with masking technology companies. For each masking technology company, a profile has been elaborated providing information about the company background/history, the financial situation, relevant technology, partnering deals and target & pipeline overview.Short profiles are provided for pharma & biotech companies with a stake in masking technologies.
The company profiles are preceded by a chapter of stakeholder analysis. Profiles of 20 different masking technologies were also elaborated and presented separately for masking technology onloy applied to antibodies, only applied to cytokines and applied to both, antibodies and cytokines.The masking technologies are analyzed with special focus on origin of technology, inactivation domain, linkers and substrates for protease cleavage.
Conventional and universal masking technologies are also discussed. Eventually, profiles of 25 masked antibody R&D programs and of 10 masked cytokine programs.Each masked antibody profile was assigned to one of three groups: immuno-oncology antibodies; antibody-drug conjugates (ADC) and T-cell engaging (TCE) bi- or trispecific antibodies.
Masked cytokine profiles are presented separately for interleukin-2 (IL-2); IL-12 & IL-15; and interferon alpha. Discussion of the masked antibody programs includes applied masking technology, targets or type of cytokine, stage of development, preclinical and clinical experience. In a separate chapter, aspects of business models, financing and partnering are presented and discussed.Further stakeholders of masking technologies include investment firms which are presented by company and investment round.
Financial terms of partnering deals are also described and discussed. All information in the three chapters of Company Profiles, Technology Profiles and Drug Candidate Profiles are fully referenced with 79 scientific references, in many cases with hyperlinks leading to the source of information (abstracts, Posters, papers).Non-scientific references, such as press releases, annual reports or company presentations, are disclosed within the text with an embedded hyperlink leading to the online source of information.
Details about R&D strategy, collaboration and licensing agreements, financing rounds & sources are described in the company profiles. The report further includes 35 tables to summarize and directly compare information and uses illustrations to explain principles of masking technologies.
What will you find in the report?
Profiles of antibody & cytokine masking technology companies active in the field; Description of major pharma’s/biotech’s role in the field (in-house R&D, partnering and investing); Comprehensive description and analysis of emerging masked antibodies and cytokines; Pharmacologic profiles of selected masked antibodies and cytokines; Characterization, profiling and state of antibody & cytokine masking technologies; Target selection for each antibody masking technology; Selection of type of cytokine for each cytokine masking technology; Description and analysis of financing rounds (capital raised, investors); Economic terms of collaboration and licensing deals; Sources of financing.
Who will benefit from the report?
Venture capital, private equity and investment managers; Managers of Big Pharma venture capital firms; Financial analysts; Business development and licensing (BDL) specialists; CEO, COO and managing directors; Corporate strategy analysts and managers; Chief Technology Officer; R&D Portfolio, Technology and Strategy Management; Clinical and preclinical development specialists.
Our reports have been used by over 10K customers, including:
175 pages •
By The Business Research Company
• Sep 2021
Major players in the remdesivir market are Gilead Sciences, Inc., Bright Gene, Hainan Haiyao, Kelun Pharma, Hunan Warrant Pharmaceutical, Cipla, Pfizer, Merck, Cayman Chemical, and Dr. Reddy’s Laboratories. The global remdesivir market is expected to grow from $1.98 billion in 2020 to $2.55 billion in 2021 at a compound annual growth...
The global single-use bioreactors market is projected to reach USD 8.8 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 21.1% during the forecast period. Increasing adoption of SUBs among small companies and startups, reduced automation complexity, ease in the cultivation of marine organisms, reduced energy and water consumption,...
The global biologics market exhibited strong growth during 2015-2020. Looking forward, the analyst expects the market to grow at a CAGR of 9% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different...
The Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies. This report provides details of the latest...
The Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015- 2021 report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies. This report provides details of the latest licensing...
Global Coronavirus Partnering 2014 to 2021 provides the full collection of Coronavirus disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Coronavirus partnering deals Financial deal terms for headline, upfront and royalty by stage of development Coronavirus...
120 pages •
By Infiniti Research Limited
• Sep 2021
Global Humanized Mouse Model Market 2021-2025 The analyst has been monitoring the humanized mouse model market and it is poised to grow by $ 119.20 mn during 2021-2025, decelerating at a CAGR of over 14% during the forecast period. Our report on the humanized mouse model market provides a holistic analysis, market size...
The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021 report provides a detailed understanding and analysis of how, why and what terms companies enter preclinical stage partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization...
Global TROP2 Antibody Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights: • Research Methodology • Global & Regional Market Analysis • Global TROP2 Antibody Market Opportunity Assessment: > USD 4 Billion • Market and Drug Sales Insight 2020 Till 2026 • Approved Drug In Market: 1 Drugs • Approved...
The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies. This report provides...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.